# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-210355
Filing Date
2026-05-07
Accepted
2026-05-07 07:30:40
Documents
64
Period of Report
2026-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | rapp-20260331.htm iXBRL | 10-Q | 2420398
2 | EX-10.1 | rapp-ex10_1.htm | EX-10.1 | 76559
3 | EX-31.1 | rapp-ex31_1.htm | EX-31.1 | 19325
4 | EX-31.2 | rapp-ex31_2.htm | EX-31.2 | 18171
5 | EX-32.1 | rapp-ex32_1.htm | EX-32.1 | 16175
| Complete submission text file | 0001193125-26-210355.txt |  | 8982683

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | rapp-20260331.xsd | EX-101.SCH | 1300776
68 | EXTRACTED XBRL INSTANCE DOCUMENT | rapp-20260331_htm.xml | XML | 1437115

Mailing Address 99 HIGH STREET SUITE 2100 BOSTON MA 02110
Business Address 99 HIGH STREET SUITE 2100 BOSTON MA 02110 857-321-8020
Rapport Therapeutics, Inc. (Filer) CIK: 0002012593 (see all company filings)

EIN.: 880724208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42121 | Film No.: 26950887
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)